For the year ending 2025-12-31, MBOT had $810K increase in cash & cash equivalents over the period. -$13,106K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -13,142 |
| Depreciation of property and equipment | 47 |
| Share-based compensation | 1,057 |
| Inventory | 584 |
| Prepaid expenses and other assets | 182 |
| Accounts payable and accrued liabilities | 495 |
| Change in long-term deposit | 737 |
| Net cash flows used in operating activities | -13,046 |
| Purchase of property and equipment | 60 |
| Purchase of marketable securities | 82,926 |
| Proceeds from sales of marketable securities | 10,602 |
| Net cash flows (used in) provided by investing activities | -72,384 |
| Issuance of common stock and warrants, net of issuance costs | 86,239 |
| Exercise of options | 1 |
| Net cash flows provided by financing activities | 86,240 |
| Increase in cash, cash equivalents and restricted cash | 810 |
| Cash, cash equivalents and restricted cash at beginning of year | 3,163 |
| Cash, cash equivalents and restricted cash at ending of year | 3,973 |
Microbot Medical Inc. (MBOT)
Microbot Medical Inc. (MBOT)